Chronic HCV Infection: Clinical Advances and Eradication Perspectives

Hepatitis C virus (HCV) chronic infection can determine liver fibrosis, cirrhosis and hepatocellular carcinoma, as well as several extra-hepatic manifestations (i.e., mixed cryoglobulinemia, metabolic syndrome, kidney disease, etc.). HCV infection is asymptomatic until severe stages of disease, thus...

Full description

Saved in:
Bibliographic Details
HerausgeberIn:
Sonstige:
Year of Publication:2022
Language:English
Physical Description:1 electronic resource (104 p.)
Tags: Add Tag
No Tags, Be the first to tag this record!
LEADER 03043nam-a2200685z--4500
001 993545953004498
005 20231214133343.0
006 m o d
007 cr|mn|---annan
008 202203s2022 xx |||||o ||| 0|eng d
035 |a (CKB)5400000000045316 
035 |a (oapen)https://directory.doabooks.org/handle/20.500.12854/79675 
035 |a (EXLCZ)995400000000045316 
041 0 |a eng 
100 1 |a Liberto, Maria Carla  |4 edt 
245 1 0 |a Chronic HCV Infection: Clinical Advances and Eradication Perspectives 
246 |a Chronic HCV Infection 
260 |a Basel  |b MDPI - Multidisciplinary Digital Publishing Institute  |c 2022 
300 |a 1 electronic resource (104 p.) 
336 |a text  |b txt  |2 rdacontent 
337 |a computer  |b c  |2 rdamedia 
338 |a online resource  |b cr  |2 rdacarrier 
520 |a Hepatitis C virus (HCV) chronic infection can determine liver fibrosis, cirrhosis and hepatocellular carcinoma, as well as several extra-hepatic manifestations (i.e., mixed cryoglobulinemia, metabolic syndrome, kidney disease, etc.). HCV infection is asymptomatic until severe stages of disease, thus screening policy in the general population and in specific risk categories is necessary to allow for timely intervention. Despite a high sustained virological response by direct-acting antiviral drugs, a limited percentage of treated subject failed therapy according to resistance associated substitution carried on viral isolates and comorbidities in infected patients. Therefore, tailored therapy is required to cure HCV infection. Failure to comply with these conditions may impair success of HCV eradication expected by 2030. This Special Issue aims to discuss eradication perspectives related to therapy efficacy in patients with chronic diseases, developments in diagnostic procedures and improvements in screening policy. 
546 |a English 
650 7 |a Medicine  |2 bicssc 
650 7 |a Epidemiology & medical statistics  |2 bicssc 
653 |a HCV 
653 |a rheumatic 
653 |a interferon 
653 |a mortality 
653 |a hepatitis C virus (HCV) 
653 |a phylogeny 
653 |a resistance-associated substitution (RAS) 
653 |a chronic hepatitis C 
653 |a vibration controlled transient elastography 
653 |a fibrosis 
653 |a steatosis 
653 |a hepatocellular carcinoma 
653 |a hepatitis C 
653 |a genotype 3 
653 |a liver cirrhosis 
653 |a pangenotypic 
653 |a children 
653 |a ledipasvir/sofosbuvir 
653 |a real-life 
653 |a sustained virological response 
653 |a elimination 
653 |a model 
653 |a COVID-19 
653 |a PWID 
653 |a homeless persons 
653 |a HCV eradication 
653 |a direct-acting antivirals 
653 |a out-of-hospital 
653 |a retention in care 
776 |z 3-0365-3361-3 
776 |z 3-0365-3362-1 
700 1 |a Marascio, Nadia  |4 edt 
700 1 |a Liberto, Maria Carla  |4 oth 
700 1 |a Marascio, Nadia  |4 oth 
906 |a BOOK 
ADM |b 2023-12-15 05:51:15 Europe/Vienna  |f system  |c marc21  |a 2022-04-04 09:22:53 Europe/Vienna  |g false 
AVE |i DOAB Directory of Open Access Books  |P DOAB Directory of Open Access Books  |x https://eu02.alma.exlibrisgroup.com/view/uresolver/43ACC_OEAW/openurl?u.ignore_date_coverage=true&portfolio_pid=5338078460004498&Force_direct=true  |Z 5338078460004498  |b Available  |8 5338078460004498